{
    "clinical_study": {
        "@rank": "112472", 
        "arm_group": [
            {
                "arm_group_label": "Methylene Blue MMX\u00ae 200mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral dose, 8 Methylene Blue MMX\u00ae tablets over a 4hr schedule"
            }, 
            {
                "arm_group_label": "Methylene Blue MMX\u00ae 100mg", 
                "arm_group_type": "Active Comparator", 
                "description": "Oral dose, 4 Methylene Blue MMX\u00ae tablets and 4 Placebo tablets over a 4hr schedule"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Oral dose, 8 Placebo tablets over a 4hr schedule"
            }
        ], 
        "brief_summary": {
            "textblock": "Evaluation of the histologically proven adenoma and carcinoma detection rate in patients\n      undergoing a full colonoscopy with and without mucosal contrast enhancement, obtained with\n      200 mg of Methylene Blue MMX\u00ae tablets."
        }, 
        "brief_title": "The Safety and Efficacy of Methylene Blue MMX\u00ae Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy", 
        "completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Males or females, aged between 50 and 75.\n\n          -  Outpatients scheduled for screening or surveillance colonoscopy for polyps or\n             colorectal cancer )\n\n          -  Able to comprehend the full nature and purpose of the study, including possible risks\n             and side effects.\n\n          -  Able to co-operate with the investigator and to comply with the requirements of the\n             entire study.\n\n          -  Signed written informed consent prior to inclusion in the study.\n\n        Exclusion Criteria:\n\n          -  Patients at high risk of colorectal cancer e.g. ulcerative colitis\n\n          -  Previous medical history of, or suspected hypersensitivity to, the Methylene Blue\n             and/or formulations' ingredients.\n\n          -  Previous medical history of, or suspected hypersensitivity to, the PEG based bowel\n             cleansing preparation and/or bowel cleansing formulations' ingredients.\n\n          -  Previous medical history of gastrointestinal obstruction or perforation, toxic\n             megacolon, major colonic resection, severe diverticulitis, heart failure (Class III\n             or IV), serious cardiovascular disease, ulcerative colitis or Crohn's disease."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "75 Years", 
            "minimum_age": "50 Years"
        }, 
        "enrollment": {
            "#text": "1270", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01694966", 
            "org_study_id": "CB-17-01/06", 
            "secondary_id": "2012-003983-32"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Methylene Blue MMX\u00ae 200mg", 
                    "Methylene Blue MMX\u00ae 100mg"
                ], 
                "intervention_name": "Methylene Blue MMX\u00ae", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Investigational Product: Methylene Blue MMX\u00ae modified release tablets", 
                    "Active Ingredient: Methylene Blue"
                ]
            }, 
            {
                "arm_group_label": [
                    "Methylene Blue MMX\u00ae 100mg", 
                    "Placebo"
                ], 
                "description": "Sugar pill manufactured to mimic Methylene Blue MMX\u00ae tablet.", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Methylene Blue"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "January 10, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Scottsdale", 
                        "country": "United States", 
                        "state": "Arizona", 
                        "zip": "85259"
                    }, 
                    "name": "Dr Francesco Ramirez"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Jacksonville", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32224"
                    }, 
                    "name": "Dr Michael Wallace"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kansas City", 
                        "country": "United States", 
                        "state": "Kansas", 
                        "zip": "66103"
                    }, 
                    "name": "Dr Prateek Sharma"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Dr Marcia Canto"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dr Ram Chuttani"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rochester", 
                        "country": "United States", 
                        "state": "Minnesota", 
                        "zip": "55905"
                    }, 
                    "name": "Dr David Bruining"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Leuven", 
                        "country": "Belgium"
                    }, 
                    "name": "Dr Raf Bisschop"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5B 1W8"
                    }, 
                    "name": "Dr Norman Marcon"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany"
                    }, 
                    "name": "Dr Ralph Kiesslich"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rozzano", 
                        "country": "Italy"
                    }, 
                    "name": "Dr Alessandro Repici"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Amsterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Dr Evelien Dekker"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rotterdam", 
                        "country": "Netherlands"
                    }, 
                    "name": "Dr Manoon Spander"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Utrecht", 
                        "country": "Netherlands"
                    }, 
                    "name": "Dr Peter Siersema"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Oxford", 
                        "country": "United Kingdom"
                    }, 
                    "name": "Dr James East"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Belgium", 
                "Canada", 
                "Germany", 
                "Italy", 
                "Netherlands", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "3", 
        "official_title": "The Safety and Efficacy of Methylene Blue MMX\u00ae Modified Release Tablets Administered to Subjects Undergoing Screening or Surveillance Colonoscopy", 
        "overall_contact": {
            "email": "rwyer@cosmopharma.com", 
            "last_name": "Rose Wyer", 
            "phone": "+35318170384"
        }, 
        "overall_official": [
            {
                "affiliation": "Co-ordinating Investigator", 
                "last_name": "Alessandro Repici, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Co-ordinating Investigator", 
                "last_name": "Michael Wallace, MD", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "To assess the detection efficacy of chromoendoscopy performed with 200mg Methylene Blue MMX\u00ae 25 mg tablets versus placebo tablets (white light endoscopy) in terms of the proportion of subjects with at least one histologically proven adenoma or carcinoma.", 
            "safety_issue": "No", 
            "time_frame": "+7 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01694966"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Cosmo Technologies Ltd", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Cosmo Technologies Ltd", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}